A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

910

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

June 9, 2025

Study Completion Date

June 9, 2025

Conditions
Influenza Immunization
Interventions
BIOLOGICAL

Quadrivalent Influenza mRNA Vaccine MRT5421

Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection

BIOLOGICAL

Quadrivalent Influenza mRNA Vaccine MRT5424

Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection

BIOLOGICAL

Quadrivalent Influenza mRNA Vaccine MRT5429

Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection

BIOLOGICAL

Quadrivalent Influenza Standard Dose Vaccine

Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection

BIOLOGICAL

Quadrivalent Influenza High-Dose Vaccine

Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection

BIOLOGICAL

Quadrivalent Recombinant Influenza Vaccine

Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection

Trial Locations (20)

14609

Rochester Clinical Research. Inc.- Site Number : 8400005, Rochester

21104

Investigational Site Number : 3400001, San Pedro Sula

29405

Coastal Carolina Research Center- Site Number : 8400014, North Charleston

32607

SIMEDHealth, LLC- Site Number : 8400011, Gainesville

33012

Indago Research and Health Center- Site Number : 8400032, Hialeah

33024

Cenexel Research Centers of America- Site Number : 8400037, Hollywood

33135

Suncoast Research Group, LLC- Site Number : 8400015, Miami

37909

AMR Knoxville- Site Number : 8400043, Knoxville

40509

AMR Lexington- Site Number : 8400042, Lexington

46260

Brengle Family Medicine Site Number : 8400045, Indianapolis

64114

The Alliance for Multispecialty Research - KCM, LLC- Site Number : 8400034, Kansas City

68134

Velocity Clinical Research, Omaha- Site Number : 8400008, Omaha

68701

Velocity Clinical Research Norfolk- Site Number : 8400046, Norfolk

70119

Velocity Clinical Research- New Orleans Site Number : 8400053, New Orleans

78229

Clinical Trials of Texas, Inc. - PPDS- Site Number : 8400029, San Antonio

84107

Cenexel JBR- Site Number : 8400051, Salt Lake City

90806

Long Beach Clinical Trials Site Number : 8400013, Long Beach

92123-1881

California Research Foundation Site Number : 8400038, San Diego

32720-0834

Accel Clinical Research-Deland Clinical Research Unit- Site Number : 8400001, DeLand

00694

Investigational Site Number : 6300002, Barrio Sabana

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT06361875 - A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above | Biotech Hunter | Biotech Hunter